Lilly Blood Clot Treatment Results Could Be New Headache For Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I study demonstrates potential advantages of prasugrel over clopidogrel in onset of action, clotting activity.
You may also be interested in...
Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel
Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.
Lilly, Daiichi Sankyo Suspend Enrollment In Phase II Trials Of Prasugrel
Analysis of “a number of studies” underlies decision to temporarily suspend enrollment to consider dosing changes for the anti-platelet therapy, Lilly tells “The Pink Sheet” DAILY.
Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the anti-platelet drug prasugrel that Daiichi is developing with Lilly, Daiichi’s planned sales force expansion, and his views on partnering in the U.S. and Asia.